Outcome of Board Meeting

Jagsonpal Pharmaceuticals Ltd ( ::.:&.mu • -~ Sakht Corporate Office: Plot l\b. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India) Ph.: +91124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com A CSR Initiative lJAGSONPAL! CIN. : L74899DL1978PLC009181 July 29, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Outcome of Board Meeting held on July 29, 2026 along with Unaudited (Standalone) Financial Results for the quarter June 30, 2026 Dear Sir/ Madam, Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, Unaudited Financial Results for the quarter ended June 30, 2026. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2026. The Board Meeting commenced at 03:45 p.m. and concluded at 04:17 p.m. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance officer Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India) Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070 Walker Chandiok &_Co LLP Walker Chandlok & Co LLP 2191 Floor, DLF Square Jacaranda Marg, DLF Phase II Gurugram - 122 002 India T +91 124 4628099 F +91 124 4628001 Independent Auditor's Review Report on Unaudited Quarterly Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Jagsonpal Pharmaceuticals Limited 1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Jagsonpal Pharmaceuticals Limited ('the Company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Chartered Accountants Walker Chandlok & Co LLP is registered with imked liability with ldentlflcatlon number AAC-2085 and its Offices in Bengaluru, Chandigarh, Chennai. Gurugram. Hyderabad, Koehl, Kolkata, Mumbai, New Delhi, registered office at L-41 Connaught Circus, New Nolda and Pune Delhi, 110001, India Walker Chandiok &..Co LLP Independent Auditor's Review Report on Unaudited Quarterly Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 su.J.o"' Mo.cl'-"~ :::--:--; Madhu Sudan Malpani """' Partner Membership No. 517440 ~ FDAcC(l~ UDIN: 26517440NJFRTQ2097 Place: Gurugram Date: 29 July 2026 Jagsonpal Pharmaceuticals Limited Registered office: lnnovB 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi, 110020 Corporate office: Plot No. 412-415,3rd Floor, Nimai Tower, Phase-IV, Udyog Vihar, Sector 18, Gurugram, Haryana-122015 CIN No:-L74899DL1978PLC009181 Phone:0124-4406710 Statement of Unaudited Financial Results for the Quarter Ended 30 June 2026 (Rs. In MIiiion) Quarter Ended Year Ended Sr. No. Particulars 30 June 31 March 30 June 31 March (Unaudited) (Audited) (Unaudited) (Audited) 2026 2026 2025 2026 INCOME 1 Revenue from operations 822.32 642.03 756.12 2,872.25 2 Other income 28.33 31.68 28.25 119.95 3 Total mcome (1+2) 850.65 673.71 784.37 2,992.20 4 EXPENSES a) Cost of materials consumed 48.66 29.87 53.32 161.13 b) Purchases of stock-in-trade 260.50 198.88 226.89 891.88 c) Changes in inventories of finished goods, stock-in-trade and work-In-progress (22.92) 8.92 (10.94) (9.26) d) Employee benefits expense 227.78 155.45 194.41 707.40 e) Finance costs 2.51 2.52 2.54 10.28 f) Depreciation and amortisation expenses 21.42 23.19 23.53 94.44 g) Other expenses 135.90 137.32 150.31 540.36 - - - - - Total expenses 673.85 556.15 640.06 2,396.23 5 Profit before exceptional items and tax (3-4) 176.80 117.56 144.31 595.97 7 Profit before tax (5+6) 176.80 117.56 144.31 575.18 8 Tax expense: Current tax (including earlier years) 41.78 24.60 31.71 131.87 Deferred tax charge 3.13 5.34 4.65 12.49 9 Net profit for the period/year (7-8) 131.89 87.62 107.95 430.82 10 Other comprehensive income (OCI) I) a) Items that will not be reclassified to profit or loss 1.26 1.47 0.76 4.86 b) Income tax relating to items that will not be reclassified to profit or loss (0.32) (0.37) (0.19) (1.22) II) a) Items that will be reclassified to profit or loss - - - - b) Income tax relating to items that will be reclassified to profit or loss - - - - 11 Total comprehensive income for the period/year (9+10) 132.83 88.72 108.52 434.46 12 Earnings per share (not annualised for the quarters) Basic (Rs.) 2.00 1.25 1.60 6.40 DIiuted (Rs.) 1.98 1.21 1.58 6.31 13 Paid-up equity share capital (face value per share Rs. 2) 131.68 133.93 133.06 133.93 14 Reserves excluding revaluation reserves (other equity) 2,627.79 See accompanying notes to the Unaudited Financial Results SIGNED FOR IDENTIFICATION PURPOSES ONLY Notes to the unaudited flnandal results: 1. The unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of [Showing first 8,000 characters — download PDF for full document]